Hvis uplanlagte laboratorieresultater under en behandlingscyklus viser, at neutrofiltallet falder til under 1, 0 x 109/ l, eller antallet af blodplader falder til under 75 x 109/ l, bør behandling med Xeloda seponeres.
If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 109/ L or that the platelet count drops below 75 x 109/ L, treatment with Xeloda should be interrupted.